N-<2-(4-Methyl-phenylsulfonyl)-aethyl>-dimethyl-amin | 3405-98-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-<2-(4-Methyl-phenylsulfonyl)-aethyl>-dimethyl-amin
• 英文别名: N,N-dimethyl-2-(4-methylphenyl)sulfonylethanamine
• CAS: 3405-98-9
• 化学式: C₁₁H₁₇NO₂S
• 分子量: 227.327
• InChiKey: CFAZCTSUSLANQY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  45.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  对甲苯基乙烯基砜 、 二甲胺 以 乙醇 为溶剂， 生成 N-<2-(4-Methyl-phenylsulfonyl)-aethyl>-dimethyl-amin
  参考文献：
  名称：

  消除-加法。第十部分胺向对甲苯基砜的加成速率

  摘要：

  除对甲苯基乙烯基砜外，胺的反应性已通过竞争反应（在苯中）和通过单独的速率测量（在苯和醇中）进行了测定。

  DOI：

  10.1039/j29670000343

文献信息

• [EN] INDOLE DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS DE D'INDOLE ET LEURS UTILISATIONS
  申请人：NOVARTIS AG

  公开号：WO2019021059A1

  公开（公告）日：2019-01-31

  The present disclosure provides a compound of formula (I): or a pharmaceutically acceptable salt thereof, and its therapeutic uses for activating a growth factor pathway, promoting wound healing, promoting tissue repair, and treating hearing loss, skeletal muscle loss, organ degeneration, tissue damage, neurodegeneration, and muscular atrophy. The disclosure further provides pharmaceutical compositions and combinations. The present disclosure also relates to the use of such compounds for research or other non- therapeutic purposes.

  本公开提供了一种公式(I)的化合物：或其药用可接受的盐，及其用于激活生长因子途径、促进伤口愈合、促进组织修复以及治疗听力损失、骨骼肌损失、器官退化、组织损伤、神经退行性和肌肉萎缩的治疗用途。本公开还提供了药物组合物和组合物。本公开还涉及将此类化合物用于研究或其他非治疗目的。
• Application of Mannich Reaction to Sulfones I
  作者：W. Lewis Nobles、B. Blackburn Thompson

  DOI：10.1002/jps.2600540418

  日期：1965.4

  The preparation of a series of β -aminosulfones is described. Consideration of sulfone reactivity and mechanism of the condensaion are related in this report. These compounds failed to provide significant antibacterial activity.

  描述了一系列β-氨基砜的制备。本报告涉及砜反应性的考虑和冷凝的机理。这些化合物不能提供显着的抗菌活性。
• CHIRAL DESIGN
  申请人：WAVE LIFE SCIENCES LTD.

  公开号：US20170037399A1

  公开（公告）日：2017-02-09

  The present invention relates to chirally controlled oligonucleotides of select designs, chirally controlled oligonucleotide compositions, and methods of making and using the same. In some embodiments, a provided chirally controlled oligonucleotide composition provides different cleavage patterns of a nucleic acid polymer than a reference oligonucleotide composition. In some embodiments, a provided chirally controlled oligonucleotide composition provides single site cleavage within a complementary sequence of a nucleic acid polymer.